Trial Profile
Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine
- Indications Cutaneous T-cell lymphoma; Myeloid leukaemia; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma; T-cell prolymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Final clinical results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results assessing the stimulatory effects of m-rom on the graft-versus-malignancy effect through NK-cells post-allo-SCT presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 18 Apr 2022 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.